- Home
- EHI vs AVR Comparison
EHI vs AVR Comparison
Compare EHI & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- AVR
- Stock Information
- Founded
- EHI 2003
- AVR 1999
- Country
- EHI United States
- AVR Australia
- Employees
- EHI N/A
- AVR N/A
- Industry
- EHI Investment Managers
- AVR
- Sector
- EHI Finance
- AVR
- Exchange
- EHI Nasdaq
- AVR NYSE
- Market Cap
- EHI 194.8M
- AVR 162.1M
- IPO Year
- EHI N/A
- AVR 2024
- Fundamental
- Price
- EHI $6.49
- AVR $3.17
- Analyst Decision
- EHI
- AVR Strong Buy
- Analyst Count
- EHI 0
- AVR 4
- Target Price
- EHI N/A
- AVR $16.50
- AVG Volume (30 Days)
- EHI 44.5K
- AVR 314.1K
- Earning Date
- EHI 01-01-0001
- AVR 08-16-2025
- Dividend Yield
- EHI 11.54%
- AVR N/A
- EPS Growth
- EHI N/A
- AVR N/A
- EPS
- EHI N/A
- AVR N/A
- Revenue
- EHI N/A
- AVR $2,493,000.00
- Revenue This Year
- EHI N/A
- AVR $33.26
- Revenue Next Year
- EHI N/A
- AVR $194.42
- P/E Ratio
- EHI N/A
- AVR N/A
- Revenue Growth
- EHI N/A
- AVR N/A
- 52 Week Low
- EHI $6.00
- AVR $2.34
- 52 Week High
- EHI $7.75
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- EHI 51.62
- AVR N/A
- Support Level
- EHI $6.49
- AVR N/A
- Resistance Level
- EHI $6.58
- AVR N/A
- Average True Range (ATR)
- EHI 0.05
- AVR 0.00
- MACD
- EHI -0.00
- AVR 0.00
- Stochastic Oscillator
- EHI 54.70
- AVR 0.00
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Energy, Healthcare, Industrials, materials, and others.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.